Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 40Breast Neoplasms 23Gliosarcoma 22Esophageal Neoplasms 21Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Rectal Neoplasms 13Glioma 13Brain Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 12Lung Neoplasms 11Head and Neck Neoplasms 11Melanoma 10Astrocytoma 10Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Central Nervous System Neoplasms 8Stomach Neoplasms 7Lymphoma, Follicular 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Adenocarcinoma Of Esophagus 6Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lymphoma 5Carcinoma 5Burkitt Lymphoma 5

Interventions

sintilimab 1camrelizumab 1Radiation 1Paclitaxel 1Ocoxin 1Fluorouracil 1Esophagectomy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Diseases × Radiation × Clear all
NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Hangzhou Cancer Hospital

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡